Research programme: apolipoprotein B100 gene therapy - uniQure

Drug Profile

Research programme: apolipoprotein B100 gene therapy - uniQure

Alternative Names: ApoB100 gene therapy - uniQure

Latest Information Update: 16 Jul 2012

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amsterdam Molecular Therapeutics
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hypercholesterolaemia

Most Recent Events

  • 16 Jul 2012 Discontinued - Preclinical for Hypercholesterolaemia in Netherlands (IV)
  • 25 Oct 2010 Preclinical pharmacodynamics data in Hypercholesterolaemia released by Amsterdam Molecular Therapeutics
  • 20 May 2010 Preclinical trials in Hypercholesterolaemia in Netherlands (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top